Concepedia

L. Nastoupil

LN

Statistics

Publications

3

Citations

105

H-Index

3

Active since

2016

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

L. Nastoupil is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, immunotherapy, and rituximab-based therapy.

Publications per year

2016–2018

3

Publications

3

Four‐year follow‐up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>MCL</scp>)

Preetesh Jain, Jorge Romaguera, Samer A. Srour et al. · British Journal of Haematology · 2018 · 62 citations

, , +15

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Chan Y. Cheah, Dai Chihara, S. Horowitz et al. · Annals of Oncology · 2016 · 31 citations · Full text

, , +12

HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY

L. Nastoupil, Jason R. Westin, Nathan Fowler et al. · Hematological Oncology · 2017 · 12 citations · Full text

, , +17

1–3 of 3